

# Stereotactic body radiotherapy for multisite extracranial

Cancer

118, 2962-2970

DOI: [10.1002/cncr.26611](https://doi.org/10.1002/cncr.26611)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Histology-Specific Metastasis. Medical Radiology, 2011, , 331-343.	0.0	0
2	Stereotactic Body Radiotherapy for Metachronous Multisite Oligo-Recurrence: A Long-Surviving Case with Sequential Oligo-Recurrence in Four Different Organs Treated Using Locally Radical Radiotherapy and a Review of the Literature. Pulmonary Medicine, 2012, 2012, 1-11.	0.5	13
3	Stereotactic body radiotherapy treatment of extracranial metastases. Nature Reviews Clinical Oncology, 2012, 9, 654-665.	12.5	40
4	Reirradiation for recurrent head and neck cancer. Expert Review of Anticancer Therapy, 2012, 12, 1177-1189.	1.1	27
5	Radical Treatment of Non-“Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450). Journal of Thoracic Oncology, 2012, 7, 1547-1555.	0.5	251
6	Limited M1 Disease: A Significant Prognostic Factor for Stage IV Breast Cancer. Annals of Surgical Oncology, 2012, 19, 3028-3034.	0.7	20
7	Stereotactic body radiation therapy for metastasis to the adrenal glands. Expert Review of Anticancer Therapy, 2012, 12, 1613-1620.	1.1	12
8	The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiation Oncology, 2012, 7, 216.	1.2	33
9	A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiation Oncology, 2012, 7, 164.	1.2	48
10	CyberKnife robotic image-guided stereotactic radiotherapy for oligometastatic cancer. Strahlentherapie Und Onkologie, 2013, 189, 448-455.	1.0	26
11	Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer, 2013, 82, 197-203.	0.9	268
12	Stereotactic body radiotherapy for oligometastases. Lancet Oncology, The, 2013, 14, e28-e37.	5.1	436
13	Stereotactic Body Radiation Therapy for Treatment of Primary and Metastatic Pulmonary Malignancies. Surgical Oncology Clinics of North America, 2013, 22, 463-481.	0.6	16
14	Percutaneous Cryoablation of Musculoskeletal Oligometastatic Disease for Complete Remission. Journal of Vascular and Interventional Radiology, 2013, 24, 207-213.	0.2	133
15	Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy. Clinical Genitourinary Cancer, 2013, 11, 27-32.	0.9	169
16	La radiothérapie (stéréotaxique) et le cancer broncho-pulmonaire. Revue Des Maladies Respiratoires Actualites, 2013, 5, 504-512.	0.0	1
17	Stereotactic Body Radiation Therapy for Curative Treatment of Adrenal Metastases. Technology in Cancer Research and Treatment, 2013, 12, 217-224.	0.8	58
18	Stereotactic Radiotherapy for Pulmonary Metastases. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 292-299.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. <i>Practical Radiation Oncology</i> , 2013, 3, 316-322.	1.1	23
20	The metastatic cascade and patterns of metastasis. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, S27-S28.	0.3	0
21	Ablation of a Site of Progression With Stereotactic Body Radiation Therapy Extends Sunitinib Treatment From 14 to 22 Months. <i>Journal of Clinical Oncology</i> , 2013, 31, e401-e403.	0.8	29
22	Extracranial Oligometastases: A Subset of Metastases Curable With Stereotactic Radiotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 1384-1390.	0.8	177
23	Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell-Mediated Killing. <i>Journal of Immunology</i> , 2013, 190, 5874-5881.	0.4	140
24	Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Negative Prostate Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 293.	1.3	20
25	New concepts and insights into the role of radiation therapy in extracranial metastatic disease. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1145-1155.	1.1	14
26	Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. <i>Tumori</i> , 2013, 99, 611-616.	0.6	15
27	Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. <i>Radiation Oncology</i> , 2014, 9, 258.	1.2	38
28	Surveillance or metastasis-directed Therapy for Oligometastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. <i>BMC Cancer</i> , 2014, 14, 671.	1.1	106
29	Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3824-3830.	0.8	244
30	The Role of Surgery and Ablative Radiotherapy in Oligometastatic Breast Cancer. <i>Seminars in Oncology</i> , 2014, 41, 790-797.	0.8	30
31	The oligometastatic state—separating truth from wishful thinking. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 549-557.	12.5	245
32	The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 258-264.	0.5	17
33	Extracranial oligometastatic renal cell carcinoma: current management and future directions. <i>Future Oncology</i> , 2014, 10, 761-774.	1.1	27
34	Are We Expanding Oligometastatic Non-Small-Cell Lung Cancer Using Advanced Radiotherapeutic Modalities?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3794-3796.	0.8	4
36	Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases. <i>Targeted Oncology</i> , 2014, 9, 145-153.	1.7	70
37	Local ablative treatments of oligometastases from head and neck carcinomas. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 47-63.	2.0	56

#	ARTICLE	IF	CITATIONS
38	Stereotactic body radiotherapy: A critical review for nonradiation oncologists. <i>Cancer</i> , 2014, 120, 942-954.	2.0	70
39	Radical Irradiation of Extracranial Oligometastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 2902-2912.	0.8	82
41	Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 735-748.	1.7	71
42	Thermal ablation techniques: a curative treatment of bone metastases in selected patients?. <i>European Radiology</i> , 2014, 24, 1971-1980.	2.3	107
43	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. <i>Radiation Oncology</i> , 2014, 9, 91.	1.2	81
44	Radiotherapy for renal-cell carcinoma. <i>Lancet Oncology, The</i> , 2014, 15, e170-e177.	5.1	226
45	Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases. <i>Practical Radiation Oncology</i> , 2014, 4, e143-e149.	1.1	62
46	The Role of Stereotactic Radiotherapy in the Treatment of Oligometastases. <i>Current Oncology Reports</i> , 2014, 16, 391.	1.8	3
47	Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. <i>Annals of Oncology</i> , 2014, 25, 467-471.	0.6	89
50	Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 404-412.	1.0	23
51	The role of stereotactic body radiation therapy in the management of oligometastatic lung cancer. <i>Lung Cancer Management</i> , 2015, 4, 145-153.	1.5	0
52	Surgery or Ablative Radiotherapy for Breast Cancer Oligometastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e8-e15.	1.8	21
53	SBRT: An Opportunity to Improve Quality of Life for Oligometastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 101.	1.3	15
54	Radiation Oncology and Medical Physics. <i>BioMed Research International</i> , 2015, 2015, 1-3.	0.9	2
55	PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015, 3, 610-619.	1.6	327
56	New Strategies in Stereotactic Radiotherapy for Oligometastases. <i>Clinical Cancer Research</i> , 2015, 21, 5198-5204.	3.2	79
57	Oligometastatic non-small cell lung cancer (NSCLC): adrenal metastases. Experience in a single institution. <i>Updates in Surgery</i> , 2015, 67, 383-387.	0.9	17
58	Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 524-529.	0.4	64

#	ARTICLE	IF	CITATIONS
59	Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. <i>Radiotherapy and Oncology</i> , 2015, 114, 155-160.	0.3	100
60	Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 403-410.	0.3	10
61	Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 837-842.	0.4	82
62	Stereotactic body radiation therapy for abdominal and pelvic oligometastases: Dosimetric targets for safe and effective local control. <i>Practical Radiation Oncology</i> , 2015, 5, e183-e191.	1.1	18
63	Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?. <i>Clinical Oncology</i> , 2015, 27, 411-419.	0.6	30
64	SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 87-93.	0.9	13
65	Stereotactic Body Radiotherapy for Oligometastases Confined to the Para-Aortic Region: Clinical Outcomes and the Significance of Radiotherapy Field and Dose. <i>Cancer Investigation</i> , 2015, 33, 180-187.	0.6	18
66	Stereotactic Body Radiotherapy for Oligometastatic Disease. <i>Clinical Oncology</i> , 2015, 27, 290-297.	0.6	27
67	Role for Radiation Therapy in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 323-335.	0.6	13
68	Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e279-e284.	0.9	32
69	Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 472-483.	0.3	39
70	The development of stereotactic body radiotherapy in the past decade: a global perspective. <i>Future Oncology</i> , 2015, 11, 2721-2733.	1.1	8
71	Local Therapy Options for Oligometastatic Disease in the Liver. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 241-249.	1.0	1
72	The evolving role of radiotherapy in treatment of oligometastatic NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1459-1471.	1.1	8
73	Radiation therapy for oligometastatic non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 183-193.	2.7	12
74	SBRT for lung oligometastases: Who is the perfect candidate?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 446-453.	0.3	17
75	Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e566-e575.	1.8	19
76	Local Therapy for Limited Metastatic Non-“Small Cell Lung Cancer: What Are the Options and Is There a Benefit?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e460-e467.	1.8	6

#	ARTICLE	IF	CITATIONS
77	Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 249.	1.3	27
78	Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). <i>Cancer</i> , 2016, 122, 2242-2250.	2.0	109
79	Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1078-1086.	0.4	113
80	A multi-national report on stereotactic body radiotherapy for oligometastases: Patient selection and follow-up*. <i>Acta Oncologica</i> , 2016, 55, 633-637.	0.8	26
81	Risk factors and management of oligometastatic non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 338-348.	1.0	19
82	Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. <i>Acta Oncologica</i> , 2016, 55, 1022-1028.	0.8	22
83	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 663-672.	0.4	29
84	Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 625-632.	1.1	6
85	High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 840-847.	0.4	18
86	Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. <i>Oncology Letters</i> , 2016, 12, 2139-2144.	0.8	17
87	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 6S-12S.	2.8	12
88	Stereotactic body radiotherapy for oligoprogressive cancer. <i>British Journal of Radiology</i> , 2016, 89, 20160251.	1.0	70
89	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016, 21, 964-973.	1.9	45
90	Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease. <i>Cancer Control</i> , 2016, 23, 21-29.	0.7	28
91	Stereotactic Body Radiotherapy for Oligometastasis. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 247-256.	1.0	46
92	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. <i>Breast</i> , 2016, 26, 11-17.	0.9	51
93	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2016, 91, 288-296.	1.4	17
94	The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer. <i>Lung Cancer</i> , 2016, 92, 22-28.	0.9	20

#	ARTICLE	IF	CITATIONS
95	Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. <i>Clinical Oncology</i> , 2016, 28, 13-20.	0.6	47
96	Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 696-702.	0.4	87
97	Stereotactic Treatment for Oligometastatic Breast Cancer. , 2016, , 467-481.		1
98	Ablative Approaches for Pulmonary Metastases. <i>Thoracic Surgery Clinics</i> , 2016, 26, 19-34.	0.4	12
99	Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 485-491.	0.3	101
100	Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases. <i>Clinical and Translational Oncology</i> , 2016, 18, 342-351.	1.2	9
101	Robotic Stereotactic Body Radiation Therapy in Patients With Recurrent or Metastatic Abdominopelvic Tumors. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 203-211.	0.8	2
102	Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 418-422.	0.6	124
103	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 163-169.	0.3	14
104	Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. <i>Radiotherapy and Oncology</i> , 2017, 123, 182-188.	0.3	55
105	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	12.5	760
106	Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases. <i>Clinical Oncology</i> , 2017, 29, e119-e125.	0.6	33
107	A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. <i>Future Oncology</i> , 2017, 13, 1081-1089.	1.1	13
108	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 91-100.	0.4	67
109	Ablative Therapies in Metastatic Breast Cancer: A Systematic Review. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 13-25.	1.1	29
110	Clinical relevance of the M1b and M1c descriptors from the proposed TNMÂ8 classification of lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 392-401.	1.0	5
111	Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead. <i>Cancer Letters</i> , 2017, 401, 46-52.	3.2	1
112	Expanding role of percutaneous ablative and consolidative treatments for musculoskeletal tumours. <i>Clinical Radiology</i> , 2017, 72, 645-656.	0.5	32

#	ARTICLE	IF	CITATIONS
113	The changing role of radiation therapy in the management of oligometastatic disease. Technical Innovations and Patient Support in Radiation Oncology, 2017, 1, 13-15.	0.6	1
114	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1293-1299.	1.2	26
115	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 595-606.	1.1	54
116	A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. Physics in Medicine and Biology, 2017, 62, 2859-2870.	1.6	6
117	Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry™s experience. Radiation Oncology, 2017, 12, 35.	1.2	68
118	Stereotactic ablative body radiotherapy (SABR) for oligometastatic cancer. British Journal of Radiology, 2017, 90, 20160500.	1.0	17
119	Stereotactic ablative body radiosurgery (SABR) or Stereotactic body radiation therapy (SBRT). Advanced Drug Delivery Reviews, 2017, 109, 3-14.	6.6	75
120	Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis. Acta Oncologica, 2017, 56, 1621-1625.	0.8	21
121	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. British Journal of Radiology, 2017, 90, 20170257.	1.0	14
122	Ablation of Musculoskeletal Metastases. American Journal of Roentgenology, 2017, 209, 713-721.	1.0	36
123	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU International, 2017, 120, 815-821.	1.3	53
124	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	1.8	26
125	The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going?. Cancer Treatment Reviews, 2017, 52, 22-32.	3.4	26
126	Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene, 2017, 36, 585-592.	2.6	15
127	Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Clinical Colorectal Cancer, 2017, 16, 58-64.	1.0	59
128	Stereotactic Body Radiation Therapy (SBRT) or Alternative Fractionation Schedules. Cancer Drug Discovery and Development, 2017, , 171-202.	0.2	0
129	Radiotherapy for Primary and Metastatic Soft Tissue Sarcomas: Altered Fraction Regimens with External Beam and Brachytherapy. Medical Radiology, 2017, , 307-321.	0.0	0
130	Radiotherapy for Oligometastatic Lung Cancer. Frontiers in Oncology, 2017, 7, 210.	1.3	38

#	ARTICLE	IF	CITATIONS
131	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. <i>Cancer Management and Research</i> , 2017, Volume 9, 553-563.	0.9	14
132	Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. <i>Radiation Oncology</i> , 2017, 12, 157.	1.2	28
133	Multimodality Treatment of Advanced Non-small Cell Lung Cancer: Where are we with the Evidence?. <i>Current Surgery Reports</i> , 2018, 6, 5.	0.4	33
134	Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. <i>Radiotherapy and Oncology</i> , 2018, 127, 246-252.	0.3	36
135	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 650-660.	0.4	65
136	Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. <i>Radiotherapy and Oncology</i> , 2018, 126, 519-526.	0.3	320
137	Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression. <i>Radiotherapy and Oncology</i> , 2018, 127, 493-500.	0.3	28
138	Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 53-58.	0.6	34
139	Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, e173501.	3.4	755
140	Stage I Nonsmall Cell Lung Cancer and Oligometastatic Disease. , 2018, , 342-354.e4.		0
141	Treatment planning with intensity modulated particle therapy for multiple targets in stage IV non-small cell lung cancer. <i>Physics in Medicine and Biology</i> , 2018, 63, 025034.	1.6	6
142	The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 3240-3250.	0.8	49
143	Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 23-31.	2.5	45
144	The current state of oligometastatic and oligoproliferative non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S2537-S2544.	0.6	26
145	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	0.6	2
146	Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 657-660.	0.6	6
147	Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions. <i>Annals of Translational Medicine</i> , 2018, 6, 283-283.	0.7	25
148	Thermal Ablation of Bone Metastases. <i>Seminars in Interventional Radiology</i> , 2018, 35, 299-308.	0.3	32

#	ARTICLE	IF	CITATIONS
149	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	1.2	35
150	Simulated dosimetric impact of online replanning for stereotactic body radiation therapy of lymph node oligometastases on the 1.5T MR-linac. <i>Acta Oncologica</i> , 2018, 57, 1705-1712.	0.8	24
151	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1121-1127.	0.5	59
152	Efficacy and Safety of Percutaneous Microwave Ablation and Cementoplasty in the Treatment of Painful Spinal Metastases and Myeloma. <i>American Journal of Neuroradiology</i> , 2018, 39, 1376-1383.	1.2	65
154	The role of radiation therapy in the treatment of metastatic cancer. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 535-546.	1.7	2
155	Prognostic factors in stereotactic body radiotherapy of lung metastases. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 886-893.	1.0	12
156	Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. <i>PLoS ONE</i> , 2018, 13, e0195149.	1.1	99
157	Cytokine release syndrome after radiation therapy: case report and review of the literature. , 2018, 6, 1.		54
158	Radiation Therapy for Melanoma. , 2018, , 499-514.		0
159	Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. <i>Advances in Radiation Oncology</i> , 2018, 3, 621-629.	0.6	38
160	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2018, 8, e020690.	0.8	56
162	Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1219.	1.3	27
163	Modern radiotherapy for head and neck cancer. <i>Seminars in Oncology</i> , 2019, 46, 233-245.	0.8	147
164	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
165	The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. <i>Radiotherapy and Oncology</i> , 2019, 133, 113-119.	0.3	30
166	Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, 408-419.	0.5	15
167	<p></p>Role of radiotherapy in the treatment of metastatic head and neck cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 677-683.	1.0	22
168	Oligometastatic Disease State Is Associated with Improved Local Control in Patients Undergoing Three or Five Fraction Spine Stereotactic Body Radiotherapy. <i>World Neurosurgery</i> , 2019, 122, e342-e348.	0.7	13

#	ARTICLE	IF	CITATIONS
169	NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases. <i>Practical Radiation Oncology</i> , 2019, 9, e386-e393.	1.1	10
170	Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years. <i>Frontiers in Oncology</i> , 2019, 9, 111.	1.3	9
171	Carbon-ion radiotherapy for lymph node oligo-recurrence: a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). <i>International Journal of Clinical Oncology</i> , 2019, 24, 1143-1150.	1.0	11
172	Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?. <i>Oral Oncology</i> , 2019, 93, 1-7.	0.8	32
173	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.4	30
174	The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. <i>BMC Cancer</i> , 2019, 19, 173.	1.1	68
175	Signals from SABR-COMET time to move on to phase III studies. <i>Annals of Translational Medicine</i> , 2019, 7, S316-S316.	0.7	4
176	<p>&lt;p>Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives&lt;/p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9397-9408.	0.9	10
177	Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer. <i>BMC Cancer</i> , 2019, 19, 1237.	1.1	19
178	Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. <i>Advances in Radiation Oncology</i> , 2019, 4, 201-209.	0.6	133
179	Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 879-887.	0.6	2
180	Oligometastatic breast cancer. <i>Breast Cancer</i> , 2019, 26, 138-146.	1.3	32
181	Projected clinical benefit of surveillance imaging for early detection and treatment of breast cancer metastases. <i>Breast Journal</i> , 2019, 25, 75-79.	0.4	4
182	Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study. <i>Cancer</i> , 2019, 125, 770-778.	2.0	37
183	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414.	0.8	13
184	Stereotactic Body Radiation Therapy for Extracranial Oligometastatic Non-small-cell Lung Cancer: A Systematic Review. <i>Clinical Lung Cancer</i> , 2020, 21, 95-105.e1.	1.1	10
185	Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 107-114.	0.6	11
186	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11

#	ARTICLE	IF	CITATIONS
187	Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. <i>Clinical Cancer Research</i> , 2020, 26, 6437-6444.	3.2	43
188	Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers. <i>Gynecologic Oncology</i> , 2020, 159, 611-617.	0.6	14
189	Stereotactic Body Radiation Therapy (SBRT) in Pelvic Lymph Node Oligometastases. <i>Cancer Investigation</i> , 2020, 38, 599-607.	0.6	2
191	Oligometastasis: Past, Present, Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 530-538.	0.4	27
192	Prognostic and Predictive Biomarkers in Oligometastatic Disease. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 100-107.	1.0	8
193	A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 189-195.	0.4	15
194	Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 563-569.	0.9	2
195	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020, 20, 557.	1.1	29
196	Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases. <i>BMC Cancer</i> , 2020, 20, 536.	1.1	13
197	Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 62-71.	0.4	25
198	Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature. <i>Current Oncology Reports</i> , 2020, 22, 15.	1.8	23
199	Rethinking the Role of Radiation Therapy in the Management of Epithelial Ovarian Cancer. <i>Diagnostics</i> , 2020, 10, 211.	1.3	5
200	Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. <i>Radiotherapy and Oncology</i> , 2020, 148, 82-88.	0.3	20
201	Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer. <i>JAMA Oncology</i> , 2021, 7, 92.	3.4	114
202	Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1421-1430.	0.4	7
203	Oligometastatic breast cancer: where are we now and where are we headed?â€”a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 62-62.	0.5	29
204	External Beam Radiotherapy for Thyroid Malignancy. , 2021, , 452-460.e2.		0
205	The Dutchâ€”Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1377-1386.	0.4	15

#	ARTICLE	IF	CITATIONS
206	Stereotactic Ablative Radiation (SABR) for Oligometastatic RCC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 227-234.	1.0	9
207	Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases. <i>Current Oncology</i> , 2021, 28, 2560-2578.	0.9	7
208	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3420-3431.	1.3	5
209	The Abscopal Effect in the Era of Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7204.	1.8	22
210	Imaging and its Impact on Defining the Oligometastatic State. <i>Seminars in Radiation Oncology</i> , 2021, 31, 186-199.	1.0	8
211	Radiation Therapy Planning of Thoracic Tumors: A Review of Challenges Associated With Lung Toxicities and Potential Perspectives of Gallium-68 Lung PET/CT Imaging. <i>Frontiers in Medicine</i> , 2021, 8, 723748.	1.2	12
212	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7009-7031.	0.9	0
213	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 361-375.	0.4	22
214	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	0.5	49
215	Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 804-815.	0.4	22
216	The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 34-34.	0.5	3
217	Outcomes of Stereotactic Body Radiotherapy for Metastatic Colorectal Cancer With Oligometastases, Oligoprogression, or Local Control of Dominant Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 595781.	1.3	7
218	Extracranial Oligometastases. , 2016, , 203-220.		1
219	Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. <i>Journal of Clinical Investigation</i> , 2019, 129, 786-801.	3.9	50
220	Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation Oncology. <i>PLoS ONE</i> , 2015, 10, e0124329.	1.1	13
221	Metastatic disease in head & neck oncology. <i>Acta Otorhinolaryngologica Italica</i> , 2020, 40, S1-S86.	0.7	83
222	Radiation Therapy for Melanoma. , 0, , 101-120.		5
223	Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases. <i>Tumori</i> , 2013, 99, 611-6.	0.6	10

#	ARTICLE	IF	CITATIONS
224	Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 147-156.	0.7	15
225	Robot-assisted Extracranial Stereotactic Radiotherapy of Adrenal Metastases in Oligometastatic Non-small Cell Lung Cancer. Anticancer Research, 2017, 37, 5285-5291.	0.5	19
226	The Role of Local Treatment in Oligometastatic and Oligoprogressive Cancer. Deutsches A&#x0308;rztblatt International, 2019, 116, 849-856.	0.6	6
227	Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. Journal of Thoracic Disease, 2014, 6, 369-74.	0.6	42
228	Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. Journal of Thoracic Disease, 2015, 7, 407-12.	0.6	20
229	The NEAT Predictive Model for Survival in Patients with Advanced Cancer. Cancer Research and Treatment, 2018, 50, 1433-1443.	1.3	21
230	Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World Journal of Clinical Oncology, 2019, 10, 318-339.	0.9	37
231	GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic. World Journal of Clinical Oncology, 2020, 11, 510-527.	0.9	16
232	Outcomes and toxicities in oligometastatic patients treated with stereotactic body radiotherapy for adrenal gland metastases: A multi-institutional retrospective study. Clinical and Translational Radiation Oncology, 2022, 33, 159-164.	0.9	4
233	Outcomes and Toxicities in Oligometastatic Patients Treated With Stereotactic Body Radiotherapy for Adrenal Gland Metastases: A Multi-Institutional Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, e474.	0.4	1
234	Individual strategy for oligometastatic lung cancer (NSCLC). Cureus, 2012, , .	0.2	0
235	Oligometastases. , 2015, , 219-223.		1
236	SUâ€œâ€œBRAâ€œ01: 18Fâ€œNaF PET/CTâ€œDirected Dose Escalation in Stereotactic Body Radiotherapy for Spine Oligometastases From Prostate Cancer. Medical Physics, 2015, 42, 3195-3195.	1.6	0
238	SBRT and the Treatment of Oligometastatic Disease. Cancer Treatment and Research, 2017, , 21-39.	0.2	0
239	External Radiation in Differentiated Thyroid Cancer in the Era of IMRT and Modern Radiation Planning Techniques. , 2018, , 147-152.		2
240	Will We Still Need Radiotherapy in 20ÂˆYears?. , 2019, , 191-201.		1
241	Stereotactic Body Radiation Therapy (SBRT) for Lung Metastases. , 2019, , 247-264.		0
242	Expanding the knowledge of oligometastatic diseaseâ€œbut uncertainties remain significant. Journal of Thoracic Disease, 2019, 11, S2008-S2011.	0.6	0

#	ARTICLE	IF	CITATIONS
243	Secondary Lung Cancer. , 2020, , 67-79.		0
244	Highlights on the Management of Oligometastatic Disease. Journal of Immunotherapy and Precision Oncology, 2020, 3, 34-44.	0.6	3
245	Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control. Journal of Radiosurgery and SBRT, 2014, 3, 123-129.	0.2	1
246	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancers, 2021, 13, 5773.	1.7	0
248	Role of radiotherapy in oligometastatic breast cancer: Review of the literature. World Journal of Clinical Oncology, 2022, 13, 39-48.	0.9	5
249	The markerless lung target tracking AAPM Grand Challenge (MATCH) results. Medical Physics, 2022, 49, 1161-1180.	1.6	15
250	Radiotherapy for metastatic nodal disease in colorectal cancer. , 2022, , 273-298.		0
251	Stereotactic radiotherapy for lung oligometastases. Reports of Practical Oncology and Radiotherapy, 2022, 27, 23-31.	0.3	0
252	Stereotactic radiotherapy for oligometastases in the lymph nodes. Reports of Practical Oncology and Radiotherapy, 2022, 27, 46-51.	0.3	2
253	How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation. Cancers, 2022, 14, 1705.	1.7	4
254	Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.. Indian Journal of Medical Research, 2021, 154, 303-318.	0.4	1
255	Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature. International Journal of Radiation Oncology Biology Physics, 2022, 114, 587-595.	0.4	10
256	Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. International Journal of Radiation Oncology Biology Physics, 2022, 114, 645-654.	0.4	10
257	Current treatment landscape for oligometastatic non-small cell lung cancer. World Journal of Clinical Oncology, 2022, 13, 485-495.	0.9	1
258	The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nature Reviews Clinical Oncology, 2022, 19, 585-599.	12.5	39
259	Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2022, 114, 919-935.	0.4	6
260	Patient Reported and Clinical Outcomes from 5 Fraction SBRT for Oligometastases – a Prospective Single Institution Study. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	0
261	MRI-guided Radiotherapy (MRgRT) for Treatment of Oligometastases: Review of Clinical Applications and Challenges. International Journal of Radiation Oncology Biology Physics, 2022, 114, 950-967.	0.4	10

#	ARTICLE	IF	CITATIONS
262	Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2022, 42, 3767-3778.	0.5	4
263	Clinical application of radiotherapy in patients with oligometastatic ovarian cancer: a sharp tool to prolong the interval of systemic treatment. <i>Discover Oncology</i> , 2022, 13, .	0.8	6
264	Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC. <i>Cancers</i> , 2022, 14, 3983.	1.7	3
265	Oligometastatic Head and Neck Cancer: Challenges and Perspectives. <i>Cancers</i> , 2022, 14, 3894.	1.7	9
266	Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases. <i>Clinical and Translational Radiation Oncology</i> , 2022, 36, 91-98.	0.9	1
267	Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2022, 175, 144-151.	0.3	19
268	The Emerging Role of Radiation Therapy in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4693.	1.7	10
269	Radiation Therapy for Oligometastatic Sarcomas. <i>Practical Guides in Radiation Oncology</i> , 2022, , 77-110.	0.0	0
270	Oligometastatic disease: Adrenal, lymph nodes, bone. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 375-396.	0.0	0
271	Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion. <i>Current Oncology</i> , 2023, 30, 1416-1425.	0.9	2
272	Clinical Experience of Intra-tumoral Central-Dose Escalated Volumetric Modulated Arc Therapy for Lymph Node Metastases in Patients With Advanced Cancer. <i>Cureus</i> , 2023, , .	0.2	0
273	Approaches to Oligometastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2023, 25, 251-256.	1.8	0
274	A Feasibility Study of Functional Lung Volume Preservation during Stereotactic Body Radiotherapy Guided by Gallium-68 Perfusion PET/CT. <i>Cancers</i> , 2023, 15, 1726.	1.7	2
275	Radiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2023, 33, 172-180.	1.0	2
276	The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2023, , .	0.6	0
281	Palliative radiotherapy in oligometastases. , 2024, , 263-274.		0
284	Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer. , 2023, , .		0
291	Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcinoma. , 2023, , 343-357.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------